![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Salix Pharmaceuticals has announced that rifaximin has effectively prevented the development of hepatic encephalopathy
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1660, 2008-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Rifaximin improves QoL in hepatic encephalopathy
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 603, 2010-01 ,pp. :